Phenotypes associated with this allele

• Allele Symbol: Tg(IVL-cre/ERT2)1Blpn
• Allele Name: transgene insertion 1, Cedric Blanpain
• Allele ID: MGI:4999984
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Kras^tm4Tyj/Kras^+ Tg(IVL-cre/ERT2)1Blpn/0	involves: 129S4/SvJae * C57BL/6	MGI:5298090

Genotype
MGI:5298090

cn1

• Allelic Composition: Kras^tm4Tyj/Kras⁺; Tg(IVL-cre/ERT2)1Blpn/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased facial tumor incidence ( J:172048 )

• 2-4 months following tamoxifen treatment, tumors develop in the face in 40% of treated mutants

increased lip tumor incidence ( J:172048 )

• 100% of animals develop lip tumors 2-4 months after tamoxifen treatment

increased skin tumor incidence ( J:172048 )

• 2-4 months following RU486 treatment, tumors develop in the back skin in 80% of treated mice

increased skin papilloma incidence ( J:172048 )

• tumors have hallmarks of benign papillomas with signs of squamous differentiation

• no animals develop invasive carcinoma within 4 months of tamoxifen treatment

craniofacial

increased facial tumor incidence ( J:172048 )

• 2-4 months following tamoxifen treatment, tumors develop in the face in 40% of treated mutants

increased lip tumor incidence ( J:172048 )

• 100% of animals develop lip tumors 2-4 months after tamoxifen treatment

integument

epidermal hyperplasia ( J:172048 )

• hyperplasia of the interfollicular epidermis in TAM treated mice

thick epidermis ( J:172048 )

• after tamoxifen treatment, hyperthickening of the interfollicular epidermis (IFE) is observed, indicating that hyperproliferation of IFE cells and hyperplasia of the IFE results from Kras LSL-G12D activation

increased skin tumor incidence ( J:172048 )

• 2-4 months following RU486 treatment, tumors develop in the back skin in 80% of treated mice

increased skin papilloma incidence ( J:172048 )

• tumors have hallmarks of benign papillomas with signs of squamous differentiation

• no animals develop invasive carcinoma within 4 months of tamoxifen treatment

growth/size/body

increased facial tumor incidence ( J:172048 )

• 2-4 months following tamoxifen treatment, tumors develop in the face in 40% of treated mutants

increased lip tumor incidence ( J:172048 )

• 100% of animals develop lip tumors 2-4 months after tamoxifen treatment